Wholesale Zybiraa 250mg for US Clinics | Ernest Oncology India Supply

Zybiraa 250mg Tablet: Essential Hormonal Therapy for Metastatic Prostate Cancer Management

Are you looking for a trusted Zybiraa 250 mg tablet exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hormonal therapies. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical oncology medications reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Zybiraa 250mg?

Zybiraa 250 mg is an oral hormonal therapy containing the active pharmaceutical ingredient Abiraterone Acetate. It belongs to a sophisticated class of drugs known as androgen biosynthesis inhibitors.

Manufactured by Zydus Lifesciences Ltd., Zybiraa 250mg is specifically designed to treat advanced prostate cancer. For international B2B procurement, Zybiraa offers a world-class, cost-effective alternative to innovator brands (like Zytiga), providing critical support for patients with advanced malignancies who require specialized endocrine intervention.

Primary Therapeutic Indications

Zybiraa 250 mg Tablet is clinically indicated for the following:

1. Metastatic Castration-Resistant Prostate Cancer (mCRPC): For patients whose cancer has spread and no longer responds to surgical or medical treatments that lower testosterone.

2. Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC): Often used in combination with prednisone and androgen deprivation therapy (ADT).

Mechanism of Action: How Zybiraa 250mg Works

Abiraterone acetate, the active agent in Zybiraa, functions by shutting down the production of androgens (male hormones) that fuel prostate cancer growth:

• CYP17 Enzyme Inhibition: It selectively inhibits the CYP17 enzyme complex, which is required for testosterone production.

• Multi-Source Suppression: Unlike other treatments, Zybiraa blocks testosterone production in three places: the testes, the adrenal glands, and the prostate tumor itself.

• Growth Arrest: By depriving the tumor of its "fuel," Zybiraa slows the progression of the disease and can improve survival rates in advanced cases.

Administration and Safety Guidelines

• Standard Dosage: The typical dose is 1,000mg (four 250mg tablets) taken orally once daily.

• Empty Stomach Requirement: For safety, Zybiraa must be taken on an empty stomach—at least 1 hour before or 2 hours after a meal. Taking it with food can cause the body to absorb too much of the drug.

• Key Precautions:

• Hepatotoxicity: Liver function (ALT, AST, and bilirubin) must be monitored regularly.

• Fluid Retention: It may cause high blood pressure or swelling (edema); patients with heart conditions require close monitoring.

• Potassium Levels: Monitoring for hypokalemia (low potassium) is essential.

Why Source Zybiraa 250 mg from Ernest Oncology?

• Strategic Indian Exporter: Direct access to Zydus Lifesciences’ manufacturing excellence, ensuring 100% authenticity and competitive bulk pricing.

• Logistics Mastery: Expertise in navigating the regulatory and customs landscapes of the USA, UK, Australia, and South Africa.

• Bulk Supply Reliability: We specialize in large-scale exports for oncology hospitals and regional distributors, ensuring treatment stability.

• Verified Documentation: Every shipment includes a Certificate of Analysis (COA) to facilitate seamless global customs clearance.